Haisco Pharmaceutical Group revenue and financials
¥62.18Change from previous close: +0.40%Absolute change: +¥0.25
In the fiscal year ended December 2025, Haisco Pharmaceutical Group reported revenue of ¥4.39B (+17.91% year over year). Net income was ¥259.58M, a net margin of 5.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +17.91%
- 2025 vs 2024
- Net income growth
- −34.36%
- 2025 vs 2024
- Net margin
- 5.9%
- 2024: 10.6%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 4,388 | 3,721 | 3,355 | 3,015 | — |
| Cost of revenue | 1,265 | 1,062 | 972 | 919 | — |
| Gross profit | 3,123 | 2,659 | 2,383 | 2,096 | — |
| Selling, general and administrative | 1,248 | 905 | 782 | 907 | — |
| Research and development | 804 | 624 | 517 | 448 | — |
| Operating income | 324 | 459 | 409 | 185 | — |
| EBIT | 306 | 501 | 345 | 418 | — |
| EBITDA | 584 | 750 | 564 | 602 | — |
| Interest expense | 32.5 | 37.8 | 42.3 | 50.9 | — |
| Pre-tax income | 274 | 463 | 303 | 367 | — |
| Income tax | 14.0 | -3.3 | 7.0 | -25.1 | — |
| Net income | 260 | 395 | 295 | 277 | — |
| Net income to common shareholders | 260 | 395 | 295 | 277 | — |
| Basic EPS | 0.23 | 0.35 | 0.27 | 0.26 | — |
| Diluted EPS | 0.23 | 0.35 | 0.27 | 0.26 | — |
| Average shares (basic) | 1,129 | 1,130 | 1,093 | 1,066 | — |
| Average shares (diluted) | 1,129 | 1,130 | 1,093 | 1,066 | — |